Dabigatran indications and usage

Revision as of 15:08, 31 January 2014 by ShiSheng (talk | contribs) (Created page with "__NOTOC__ {{Argatroban}} {{CMG}}; {{AE}} {{SS}} ==Indications and Usage== PRADAXA is indicated to reduce the risk of stroke and systemic embolism in patients with non-valvul...")
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to navigation Jump to search
Argatroban
Argatroban® FDA Package Insert
Indications and Usage
Dosage and Administration
Dosage Forms and Strengths
Contraindications
Warnings and Precautions
Adverse Reactions
Drug Interactions
Use in Specific Populations
Overdosage
Description
Clinical Pharmacology
Nonclinical Toxicology
Clinical Studies
How Supplied/Storage and Handling
Patient Counseling Information
Labels and Packages
Clinical Trials
ClinicalTrials.gov

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Sheng Shi, M.D. [2]

Indications and Usage

PRADAXA is indicated to reduce the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation.[1]


References

  1. "ARGATROBAN INJECTION, SOLUTION [GLAXOSMITHKLINE LLC]". Retrieved 31 January 2014.

Template:WikiDoc Sources